420 related articles for article (PubMed ID: 22595146)
1. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond.
Maeda H
J Control Release; 2012 Dec; 164(2):138-44. PubMed ID: 22595146
[TBL] [Abstract][Full Text] [Related]
2. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the enhanced permeability and retention effect for tumor targeting.
Iyer AK; Khaled G; Fang J; Maeda H
Drug Discov Today; 2006 Sep; 11(17-18):812-8. PubMed ID: 16935749
[TBL] [Abstract][Full Text] [Related]
4. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.
Maeda H
Bioconjug Chem; 2010 May; 21(5):797-802. PubMed ID: 20397686
[TBL] [Abstract][Full Text] [Related]
5. Polymer therapeutics and the EPR effect.
Maeda H
J Drug Target; 2017; 25(9-10):781-785. PubMed ID: 28988499
[TBL] [Abstract][Full Text] [Related]
6. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J; Sawa T; Maeda H
Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
[TBL] [Abstract][Full Text] [Related]
7. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
Maeda H
Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
[TBL] [Abstract][Full Text] [Related]
8. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin S; Nehoff H; Greish K
J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
Tanaka T; Shiramoto S; Miyashita M; Fujishima Y; Kaneo Y
Int J Pharm; 2004 Jun; 277(1-2):39-61. PubMed ID: 15158968
[TBL] [Abstract][Full Text] [Related]
10. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
Greish K
Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
[TBL] [Abstract][Full Text] [Related]
11. Tumor delivery of macromolecular drugs based on the EPR effect.
Torchilin V
Adv Drug Deliv Rev; 2011 Mar; 63(3):131-5. PubMed ID: 20304019
[TBL] [Abstract][Full Text] [Related]
12. [Recent advances in research on SMANCS].
Maeda H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():1-9. PubMed ID: 9512680
[TBL] [Abstract][Full Text] [Related]
13. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.
Acharya S; Sahoo SK
Adv Drug Deliv Rev; 2011 Mar; 63(3):170-83. PubMed ID: 20965219
[TBL] [Abstract][Full Text] [Related]
14. Advances in polymeric micelles for drug delivery and tumor targeting.
Kedar U; Phutane P; Shidhaye S; Kadam V
Nanomedicine; 2010 Dec; 6(6):714-29. PubMed ID: 20542144
[TBL] [Abstract][Full Text] [Related]
15. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
Maeda H
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(3):53-71. PubMed ID: 22450535
[TBL] [Abstract][Full Text] [Related]
16. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
Nakamura H; Fang J; Maeda H
Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
[TBL] [Abstract][Full Text] [Related]
17. [Clinical experience of treatment of liver metastasis of renal cell carcinoma treated with SMANCS/Lipiodol therapy].
Umeda S; Ito K; Takahashi E; Kimura F; Sumitomo M; Kaji T; Hayakawa M; Asano T
Hinyokika Kiyo; 2010 Oct; 56(10):543-9. PubMed ID: 21063157
[TBL] [Abstract][Full Text] [Related]
18. Tumoritropic and lymphotropic principles of macromolecular drugs.
Maeda H; Matsumura Y
Crit Rev Ther Drug Carrier Syst; 1989; 6(3):193-210. PubMed ID: 2692843
[TBL] [Abstract][Full Text] [Related]
19. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
Maeda H; Wu J; Sawa T; Matsumura Y; Hori K
J Control Release; 2000 Mar; 65(1-2):271-84. PubMed ID: 10699287
[TBL] [Abstract][Full Text] [Related]
20. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
